- Multi-year agreement to expand commercial footprint with world-leading 
genomics platform and develop R&D to unlock the potential of multimodal health 
data

SOPHiA GENETICS SA ("SOPHiA GENETICS"), pioneer in Data-Driven Medicine, and 
Hitachi, Ltd. (TSE: 6501, "Hitachi") today announced they have entered into a 
long-term collaboration agreement to bring clinical, genomic and real-world 
insights to healthcare providers, pharmaceutical and biopharmaceutical 
companies and extend the democratization of Data-Driven Precision Medicine 
globally for the benefit of patients. Under this agreement, the two companies 
will advance data-driven precision medicine through global commercial expansion 
and development of Hitachi's digital healthcare solutions and the SOPHiA DDM™ 
Platform.

SOPHiA GENETICS and Hitachi have identified multiple areas for potential 
collaboration including secure personal genomics data management, deployment of 
data and insights for better healthcare decisions and acceleration of drug 
development in oncology and other disease areas. Initially, the collaboration 
will focus on leveraging the genomics, clinical data analytics and AI expertise 
of both companies to expand the commercialization of the SOPHiA DDM™ Platform 
and Hitachi's digital healthcare solutions, like Hitachi's molecular tumor 
board support service, in key geographies. Over the long term, the two 
companies will also collaborate on R&D related new product development which is 
expected to lead to new joint offerings. 

"SOPHiA GENETICS is a leader in precision medicine," said Keiji Kojima, 
Executive Vice President and Executive Officer, and General Manager of Smart 
Life Business Management Division of Hitachi, Ltd. "Hitachi is excited to start 
long term partnership with SOPHiA GENETICS to co-create innovative solutions 
for improving Quality of Life of patients by leveraging both companies' data 
analytics and AI technologies."

"At SOPHiA GENETICS, we are committed to improving patient outcomes through 
data driven medicine and we are excited to collaborate with Hitachi, a global 
leader in real-world evidence and multimodal clinical decision support, who 
shares these values," said Jurgi Camblong, CEO and Founder of SOPHiA GENETICS. 
"This partnership will enable us to broaden our commercial reach and support 
improved health outcomes for more patients."

Hitachi has been offering high value-added services, such as genomics, a 
medical and care data management platform and new services utilizing AI and 
analytics. Hitachi will broaden its healthcare business by leveraging its 
strengths of in-vitro diagnostics systems, particle therapy treatment systems 
and digital technologies, to contribute to the improvement of people's quality 
of life and the realization of a sustainable society. 

The SOPHiA DDM™ Platform is a cloud-based software-as-a-service analytics 
platform that uses AI and machine learning to generate actionable insights for 
clinicians and researchers from complex multimodal datasets. These insights 
enable healthcare institutions to benefit from shared knowledge and, 
ultimately, improve diagnosis, treatment and drug development to drive better 
clinical and scientific outcomes.

About SOPHiA GENETICS

SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to 
improve health outcomes and economics worldwide. By unlocking the power of 
new-generation health data for cancer and rare diseases management, the 
universal SOPHiA DDM Platform allows clinical researchers to act with precision 
and confidence. The company's innovative approach enables an ever-expanding 
community of over 1,000 institutions to benefit from knowledge sharing, 
fostering a new era in healthcare. SOPHiA GENETICS's achievement is recognized 
by the MIT Technology Review's "50 Smartest Companies."

More info: SOPHiAGENETICS.COM [https://www.sophiagenetics.com], follow 
@SOPHiAGENETICS on Twitter [https://twitter.com/SOPHiAGENETICS].

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focused on its 
Social Innovation Business that combines information technology (IT), 
operational technology (OT) and products. The company's consolidated revenues 
for fiscal year 2019 (ended March 31, 2020) totaled 8,767.2 billion yen ($80.4 
billion), and it employed approximately 301,000 people worldwide. Hitachi 
drives digital innovation across five sectors – Mobility, Smart Life, Industry, 
Energy and IT – through Lumada, Hitachi's advanced digital solutions, services, 
and technologies for turning data into insights to drive digital innovation. 
Its purpose is to deliver solutions that increase social, environmental and 
economic value for its customers. For more information on Hitachi, please visit 
the company's website at https://www.hitachi.com.

Photo - https://mma.prnewswire.com/media/1472932/SOPHiA_GENETICS_Hitachi.jpg

SOPHiA GENETICS investor contact: Carrie Mendivil, carrie@gilmartinir.com; 
SOPHiA GENETICS media contact: Sophie Reymond, PR and Communications Manager, 
sreymond@sophiagenetics.com, +41 79 863 11 10; Hitachi media contact: PR team 
of Smart Life Business Management Division, Hitachi, Ltd., 
hc.life-pr.bb@hitachi.com